In last trading session, PDS Biotechnology Corporation (NASDAQ:PDSB) saw 0.5 million shares changing hands with its beta currently measuring 1.45. Company’s recent per share price level of $0.95 trading at -$0.1 or -9.51% at ring of the bell on the day assigns it a market valuation of $43.13M. That closing price of PDSB’s stock is at a discount of -365.26% from its 52-week high price of $4.42 and is indicating a discount of -10.53% from its 52-week low price of $1.05. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.32 million shares which gives us an average trading volume of 634.76K if we extend that period to 3-months.
For PDS Biotechnology Corporation (PDSB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.22 in the current quarter.
PDS Biotechnology Corporation (NASDAQ:PDSB) trade information
Upright in the red during last session for losing -9.51%, in the last five days PDSB remained trading in the red while hitting it’s week-highest on Monday, 03/31/25 when the stock touched $0.95 price level, adding 25.2% to its value on the day. PDS Biotechnology Corporation’s shares saw a change of -41.71% in year-to-date performance and have moved -24.60% in past 5-day. PDS Biotechnology Corporation (NASDAQ:PDSB) showed a performance of -29.10% in past 30-days. Number of shares sold short was 3.86 million shares which calculate 2.83 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 9 to the stock, which implies a rise of 89.44% to its current value. Analysts have been projecting 9 as a low price target for the stock while placing it at a high target of 9. It follows that stock’s current price would drop -847.37% in reaching the projected high whereas dropping to the targeted low would mean a loss of -847.37% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 6.42% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 7.77% while estimates for its earnings growth in next 5 years are of 0.82%.
PDS Biotechnology Corporation (NASDAQ:PDSB)’s Major holders
Insiders are in possession of 3.05% of company’s total shares while institution are holding 9.40 percent of that, with stock having share float percentage of 9.70%. Investors also watch the number of corporate investors in a company very closely, which is 9.40% institutions for PDS Biotechnology Corporation that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at PDSB for having 1.41 million shares of worth $4.13 million. And as of 2024-06-30, it was holding 4.0465 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 0.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.3271 of outstanding shares, having a total worth of $1.43 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.02 shares of worth $0.97 million or 2.24% of the total outstanding shares. The later fund manager was in possession of 456.79 shares on Dec 31, 2024 , making its stake of worth around $0.43 million in the company or a holder of 1.01% of company’s stock.
